ARTICLE | Company News
Abeona gets rights to RegenxBio gene therapy vector
November 9, 2018 6:23 PM UTC
Gene therapy company RegenxBio Inc. (NASDAQ:RGNX) granted Abeona Therapeutics Inc. (NASDAQ:ABEO) exclusive, worldwide rights to use RegenxBio's NAV adeno-associated virus 9 (AAV9) vector to develop therapies for four lysosomal storage disorders.
Abeona will pay RegenxBio $20 million up front and a total of $100 million in annual fees payable upon the second through sixth anniversaries of the deal, $20 million of which is guaranteed. RegenxBio is also eligible to receive up to $60 million in milestones and low, double-digit royalties...